219007
Caspase Inhibitor VI
Z-VAD-FMK, CAS 161401-82-7, is an irreversible pan caspase inhibitor. Does not require pretreatment with esterase for in vitro studies.
동의어(들):
Caspase Inhibitor VI, Z-VAD-FMK
로그인조직 및 계약 가격 보기
크기 선택
250 μG
₩178,640
1 MG
₩445,687
₩178,640
예상 입고일2026년 3월 06일세부사항
모든 사진(1)
크기 선택
보기 변경
250 μG
₩178,640
1 MG
₩445,687
About This Item
실험식(Hill 표기법):
C21H28FN3O7
CAS Number:
Molecular Weight:
453.46
MDL number:
UNSPSC 코드:
12352200
NACRES:
NA.54
₩178,640
예상 입고일2026년 3월 06일세부사항
추천 제품
Quality Level
분석
≥98% (HPLC)
양식
solid
제조업체/상표
Calbiochem®
저장 조건
OK to freeze
desiccated
색상
off-white
solubility
DMSO: 9 mg/mL
배송 상태
ambient
저장 온도
−20°C
SMILES string
FCC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)OCc1ccccc1)C(C)C)C)CC(=O)O
InChI
1S/C21H28FN3O7/c1-12(2)18(25-21(31)32-11-14-7-5-4-6-8-14)20(30)23-13(3)19(29)24-15(9-17(27)28)16(26)10-22/h4-8,12-13,15,18H,9-11H2,1-3H3,(H,23,30)(H,24,29)(H,25,31)(H,27,28)/t13-,15-,18-/m0/s1
InChI key
SUUHZYLYARUNIA-YEWWUXTCSA-N
일반 설명
An irreversible general caspase inhibitor. Useful for studies involving recombinant, isolated, and purified caspase enzymes. Unlike Caspase Inhibitor I (Cat. No. 627610), this inhibitor does not require pretreatment with esterase for in vitro studies. A 10 mM (1 mg/221 µl) solution of Caspase Inhibitor VI (Cat. No. 219011) in DMSO is also available.
생화학적/생리학적 작용
Cell permeable: no
Product does not compete with ATP.
Reversible: no
경고
Toxicity: Standard Handling (A)
법적 정보
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class Code
11 - Combustible Solids
WGK
WGK 1
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
시험 성적서(COA)
제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.
이미 열람한 고객
Chiara Brignola et al.
Antioxidants (Basel, Switzerland), 13(7) (2024-07-27)
Despite advancements in therapeutic strategies, the development of drug resistance and metastasis remains a serious concern for the efficacy of chemotherapy against colorectal cancer (CRC). We have previously demonstrated that low expression of ribosomal protein uL3 positively correlates with chemoresistance
Genetic reduction of mTOR extends lifespan in a mouse model of Hutchinson-Gilford Progeria syndrome.
Wayne A Cabral et al.
Aging cell, 20(9), e13457-e13457 (2021-08-29)
Hutchinson-Gilford progeria syndrome (HGPS) is a rare accelerated aging disorder most notably characterized by cardiovascular disease and premature death from myocardial infarction or stroke. The majority of cases are caused by a de novo single nucleotide mutation in the LMNA
Xiaoqing Qian et al.
Journal of cellular physiology, 236(7), 5235-5252 (2020-12-29)
Intratympanic injection of gentamicin has proven to be an effective therapy for intractable vestibular dysfunction. However, most studies to date have focused on the cochlea, so little is known about the distribution and uptake of gentamicin by the counterpart of
Amphipathic barbiturates as marine product mimics with cytolytic and immunogenic effects on head and neck squamous cell carcinoma cell lines.
von Hofsten, et al.
Frontiers in Pharmacology, 14, 1141669-1141669 (2023)
Takashi Kojima et al.
Disease models & mechanisms, 14(11) (2021-10-09)
KCNQ4 encodes the homotetrameric voltage-dependent potassium ion channel Kv7.4, and is the causative gene for autosomal dominant nonsyndromic sensorineural hearing loss, DFNA2. Dominant-negative inhibition accounts for the observed dominant inheritance of many DFNA2-associated KCNQ4 variants. In addition, haploinsufficiency has been
활성 필터
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.
